PDS Biotechnology Corp/ US70465T1079 /
2024-07-08 9:59:58 PM | Chg. +0.12 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
3.24USD | +3.85% | 11,695 Turnover: 37,640.31 |
-Bid Size: - | -Ask Size: - | 3.31 | 3.07 |
GlobeNewswire
06-12
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck ...
GlobeNewswire
05-15
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-09
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurre...
GlobeNewswire
04-23
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATIL...
GlobeNewswire
03-27
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
GlobeNewswire
03-20
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Finan...
GlobeNewswire
03-13
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Pa...
GlobeNewswire
01-22
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., ...
GlobeNewswire
01-16
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
GlobeNewswire
2023-12-04
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-11-14
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-11-09
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Tri...
GlobeNewswire
2023-11-07
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results
GlobeNewswire
2023-10-23
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head an...
GlobeNewswire
2023-10-11
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluati...
GlobeNewswire
2023-10-03
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Hea...